Catalog No.
YHG37501
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Tyr385-Cys643
Predicted molecular weight
32.12 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q13018
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
PLA2R, 180 kDa secretory phospholipase A2 receptor, Secretory phospholipase A2 receptor, PLA2-R, M-type receptor, C-type lectin domain family 13 member C, Soluble PLA2-R, PLA2R1, Soluble PLA2R, CLEC13C
The level and clinical significance of serum soluble M-type phospholipase A2 receptor in patients with primary membranous nephropathy., PMID:40462496
Regulation of podocyte surface proteins by the enzyme A Disintegrin And Metalloproteinase 10 (ADAM10)., PMID:40339751
Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports., PMID:40303416
Membranous nephropathy concurrent with renal amyloidosis: a six-patient report and literature review., PMID:40260523
Nomogram for thromboembolic events in primary membranous nephropathy associated with PLA2R antibody., PMID:40234658
Membranous Nephropathy Target Antigens Display Podocyte-Specific and Non-Specific Expression in Healthy Kidneys., PMID:40149392
Construction and validation of a predictive model for malignant tumors in patients with membranous nephropathy., PMID:40121444
Case report: Coexistence of optic neuritis and primary anti-PLA2R-positive membranous nephropathy., PMID:40119269
Adverse Prognosis in Membranous Nephropathy with Phospholipase A2 Receptor 1 Epitope Spreading: A Prospective Study., PMID:40096840
Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: results of a Nephcure membranous nephropathy workshop., PMID:40088237
Hypothetical Pathogenetic Model of Membranous Nephropathy., PMID:40076824
Role of PLA2R domain antibodies and epitope spreading in risk stratification and prediction of proteinuria remission in primary membranous nephropathy., PMID:40011527
Effectiveness of a Novel PLA2R1 Knock-In Rat Model in Repairing Renal Function Damage., PMID:39812124
Screening potential diagnostic biomarkers for PLA2R‑associated idiopathic membranous nephropathy by WGCNA analysis and LASSO algorithm., PMID:39806779
Effectiveness of a Novel PLA2R1 Knock-in Middle Age Rat Model in Repairing Renal Function Damage., PMID:39702946
Trends and the Role of Gene-Environment Interactions in Idiopathic Membranous Nephropathy in Northern China., PMID:39626635
Investigating potential drug targets for IgA nephropathy and membranous nephropathy through multi-queue plasma protein analysis: a Mendelian randomization study based on SMR and co-localization analysis., PMID:39516845
Prognostic value of serum complement cleavage factor Bb in idiopathic membranous nephropathy and establishment of nomogram model., PMID:39516318
A case of PLA2R-positive membranous nephropathy with subsequent development of IgG4-related disease., PMID:39514162
Updated diagnostic and therapeutic management for membranous nephropathy., PMID:39513350
Low-Dose Rituximab in the Treatment of Primary Membranous Nephropathy - A Systematic Review and Meta-Analysis., PMID:39508703
Animal models of membranous nephropathy: more choices and higher similarity., PMID:39497816
Establishment of a high-sensitivity time-resolved fluorescence immunoassay with PLA2R-IgG1 antibody and its clinical application in idiopathic membranous nephropathy prognosis., PMID:39491764
Treating primary membranous nephropathy with extremely high titer of anti-phospholipase A2 receptor antibodies: A case of failed treatment with very high-dose rituximab., PMID:39292007
Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection., PMID:39251782
Clinicopathological characteristics of neural epidermal growth factor-like 1 protein-associated membranous glomerulonephritis., PMID:39249508
The fate of immune complexes in membranous nephropathy., PMID:39185424
Clinicopathological features and outcomes of PLA2R-related membranous nephropathy with renal glycosuria., PMID:39099383
Mannose-Binding Lectin Deposition in Membranous Nephropathy and Differentiation of Primary from Secondary Forms., PMID:39062903
A single-center, open label, randomized, controlled study of hydroxychloroquine sulfate in the treatment of low risk PLA2R-associated membranous nephropathy., PMID:39030482
The Sensitivity and Specificity of Serum Phospholipase A2 Receptor Antibodies in Diagnosing Primary Membranous Nephropathy in Patients with Adult Nephrotic Syndrome and its Correlation with Serum Phospholipase A2 Receptor Staining in Kidney Biopsies., PMID:38995300
The correlation between anti-phospholipase A2 receptor antibodies and hypercoagulability in patients with idiopathic membranous nephropathy., PMID:38973428
The co-occurrence of sarcoidosis and anti-PLA2R-associated membranous nephropathy in a patient with underlying genetic susceptibility., PMID:38937663
Therapeutic plasmapheresis in idiopathic membranous nephropathy anti-PLA2R-related: A case series., PMID:38934513
Diagnosis of membranous nephropathy with Anti-GBM glomerulonephritis: a case series report., PMID:38907217
Ectodomain shedding of PLA2R1 is mediated by the metalloproteases ADAM10 and ADAM17., PMID:38897568
Serum Phospholipase A2 Receptor Antibody Is Associated with Thrombogenesis in Patients with Idiopathic Membranous Nephropathy., PMID:38865986
Deep analysis of total serum N-glycome suggests glyco-signatures for phospholipase A2 receptor 1-related idiopathic membranous nephropathy diagnosis., PMID:38862068
Quantification of urinary podocyte-derived migrasomes for the diagnosis of kidney disease., PMID:38853287
Phospholipid metabolism-related genotypes of PLA2R1 and CERS4 contribute to nonobese MASLD., PMID:38836837
Obinutuzumab in untreated primary membranous nephropathy: An observational case series., PMID:38830643
A Dynamic Prediction Model for Renal Progression in Primary Membranous Nephropathy., PMID:38818472
Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study., PMID:38718066
Clinical implications of serum anti-PLA2R levels and glomerular PLA2R deposits in primary membranous nephropathy., PMID:38695230
Obinutuzumab in the treatment of PLA2R-positive membranous glomerulonephritis resistant to treatment., PMID:38631964
Significance of the total renal chronicity score in predicting renal outcome in PLA2R-associated membranous nephropathy., PMID:38512370
The diversity of peripheral blood T cells and myeloid-derived suppressor cells in patients with idiopathic membranous nephropathy., PMID:38511675
Organelle resolved proteomics uncovers PLA2R1 as a novel cell surface marker required for chordoma growth., PMID:38454495
Combined Serologic and Genetic Risk Score and Prognostication of Phospholipase A2 receptor-Associated Membranous Nephropathy., PMID:38423528
Preference for anti-phospholipase A2 receptor antibody assay in patients with suspected membranous nephropathy: a survey study on medical practice after publication of Japanese Guidelines for Nephrotic Syndrome 2020., PMID:38402500
For research use only. Not for human or drug use.
